Navigation Links
Neuropathy Patients, Doctors and Medical Professionals Rally in Sacramento to Demand Access to Lifesaving Medical Treatments
Date:6/25/2009

California Assemblymember Mary Hayashi Calls on California Congressional Delegation to Remember Needs of Neuropathy Patients at 3rd Annual "Neuropathy Action Awareness Day"

SACRAMENTO, Calif., June 25 /PRNewswire/ -- As President Obama continues his push for national health care reform, more than 300 neuropathy patients, physicians and medical professionals gathered in Sacramento today to call on Congress to restore access to life-sustaining and lifesaving treatments for neuropathy patients. At a press conference kicking off the third annual "Neuropathy Action Awareness Day," California Assemblymember Mary Hayashi and those in attendance signed a petition encouraging the California Members of Congress to remember the needs of neuropathy patients while working on federal health care reform legislation.

"Neuropathy patients and advocates in California spoke with one voice today to demand access to the lifesaving treatments we need, and to help ensure that Congress protects neuropathy patients as it continues the national health care reform debate," said Michelle Vogel, Executive Director of the Alliance for Plasma Therapies. "As President Obama and Congress look for ways to cut health care spending, they must also restore access to critical therapies such as IVIG (intravenous immune globulin) which is used to treat patients suffering from neuropathy, multiple sclerosis, myositis and pemphigus, among other conditions."

Neuropathy Action Awareness Day, sponsored by the Neuropathy Action Foundation (NAF) and the Alliance for Plasma Therapies (APT), gathered patients, physicians and medical professionals and representatives from other organizations including The Neuropathy Association, Foundation for Peripheral Neuropathy and International Pemphigus and Pemphigoid Foundation to learn about neuropathy and to promote awareness of the disease. Patients and patient advocates in attendance signed a petition, to be delivered to the California Congressional delegation, which stated:

        We, the undersigned, respectfully ask the Members of Congress from the
        State of California to co-sponsor H.R. 2002 and S. 701, the Medicare
        Patient IVIG Access Act of 2009, which restores access in all sites of
        care to intravenous immune globulin (IVIG) to patients who rely on
        this lifesaving therapy.  We further ask our Members of Congress to
        remember, while debating healthcare reform, that all patients,
        especially those with rare diseases, need access to all therapies
        prescribed appropriately by their physician and that because every
        patient is unique, personalized medicine must play a role in
        diagnosing and treating patients with all diseases.

"Every time my neurologist orders a treatment, managed care denies the request, and each time I have to file an appeal to receive the treatment that my doctor thinks is best," said Stacey Westurlund, a 31-year-old social worker and neuropathy patient from Lodi, CA, who spoke at the press conference today. "I have to employ my skills as a social worker to become my own advocate - researching available treatment options, partnering with my doctors, and appealing managed care and insurance company decisions."

Westurlund, who signed the petition to Members of Congress after Assemblymember Hayashi, was misdiagnosed for a year before being diagnosed with a form of polyneuropathy. Stacey benefits from regular treatments of IVIG at home through Medicare, but because her painful condition keeps her from driving, she was forced to fight health insurers for months until she got coverage to receive her treatments at her home.

"The last major health care reform legislation passed by Congress decreased Medicare reimbursements for neuropathy patients and increased obstacles to getting timely and effective treatment," said Michelle Vogel. "In addition to restoring access to treatment for all Americans, Congress should enable physicians, not health insurers, to determine what is best for patients and what constitutes medically necessary care."

About the Neuropathy Action Foundation

The Neuropathy Action Foundation (NAF) is dedicated to ensuring neuropathy patients obtain the necessary resources, information and tools to access individualized treatment to improve their quality of life. The NAF increases awareness among physicians, appropriate institutions, the general public and public policy officials that neuropathy can potentially be a serious, widespread and disabling condition, which may be treatable when appropriate medical care is provided.

www.neuropathyaction.org

About the Alliance for Plasma Therapies

The Alliance for Plasma Therapies is a national non-profit organization established to provide a unified, powerful voice of patient organizations, healthcare providers and industry leaders to educate about the diseases that rely on plasma derived therapies and advocate for fair access to plasma therapies for patients who benefit from their lifesaving effects.

www.plasmaalliance.org


'/>"/>
SOURCE Alliance for Plasma Therapies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
7. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
8. Doctors Issue New Neuropathy Test Guidelines
9. ReBuilder Medical (RBRM) Neuropathy Market Doubles to $5 Billion
10. "Electric Socks" for Neuropathy??
11. Gene Therapy Improves Diabetic Neuropathy in Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... The National Association for Children of ... representing the growing community of recovering individuals (now over 23 million), to issue ... policies addressing addiction. , Although many of the presidential candidates of both ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly released ... visualization technology should be used to ensure patient safety when placing an IV ... Standards mandate the use of vein visualization technology in patients with difficult venous ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a Makro ... list for its expertise in eClinical Solutions. DDi has built its solution competency ... needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory and ...
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
Breaking Medicine Technology: